| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 112,85 | 112,90 | 16:17 | |
| 112,85 | 112,90 | 16:18 |
Wirklich schlecht war die Bilanz des ersten Quartals bei der im DAX notierten Merck KGaA zwar nicht. Aber das deutliche Minus der Aktie zeigt: Den Anlegern war das zu mager, zumal das Unternehmen auch noch die 2025er-Prognose senkte. Hier sollte man vorsichtig bleiben.Den vollständigen Artikel lesen ...| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Merck KGaA
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| Fr | EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Merck KGaA
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| Do | Merck KGaA sheds light on failed portion of phase 2 lupus trial, keeps sights on regulators | ||
| Do | Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 | Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the primary endpoint of BICLA dose-response relationship... ► Artikel lesen | |
| Mi | Merck KGaA's MilliporeSigma teams with Simtra in ADC manufacturing partnership |
